Coppell Advisory Solutions’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
Other funds holding NVCR
Coppell Advisory Solutions's NVCR Position: Q3 2026 in Review
Coppell Advisory Solutions reduced its NovoCure (NVCR) stake by 41% in Q3 2026, selling an estimated $265K and leaving 23,080 shares worth $369K. The position accounts for 0.04% of the portfolio, ranked #244.
Coppell Advisory Solutions first reported a position in NVCR in Q2 2024 and has held it in 5 quarters since. The position peaked at $4.86M in Q2 2026. 242 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.
- Coppell Advisory Solutions held 23,080 shares of NovoCure worth $369K as of Q3 2026.
- Coppell Advisory Solutions sold 15,873 NovoCure shares in Q3 2026, an estimated $265K.
- NovoCure made up 0.04% of Coppell Advisory Solutions's portfolio in Q3 2026, its #244 holding.
- Coppell Advisory Solutions first reported a position in NovoCure in Q2 2024 and has held it in 5 quarters since.
- Coppell Advisory Solutions's NovoCure position peaked at $4.86M in Q2 2026.
- 242 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.
Based on Coppell Advisory Solutions's 13F filing for Q3 2026, filed 16 Nov 2026.